However, it really is unlikely that might have acquired a huge effect on the outcomes given the email address details are in keeping with previously reported threat of CV final results associated with a number of the NSAIDs. Among the Retinyl acetate strengths of the evaluation was a in depth search technique was used to recognize all relevant research which is unlikely that any important trial was missed within this evaluation. All prior analysis upon this topic possess viewed, and included, unlicensed and supratherapeutic doses of the many NSAIDs within their analysis. slightly elevated risk for MI (OR 1.33, 1 comparator), the self-confidence period included 1 and had not been significant. For the supplementary endpoints, etoricoxib and rofecoxib had been considerably worse off for HT (1 comparator each) and naproxen was considerably worse off for heart stroke (1 comparator). Although ibuprofen was worse off for HT (1 comparator) the elevated risk had not been significant. Bottom line: In the analysis conducted, it would appear that the chance for cardiovascular occasions in arthritis sufferers on licensed dosages of NSAIDs varies significantly and will probably depend on the average person compound. calcium mineral antagonist structured therapies as first-line medications for hypertension recommended a considerably higher threat of severe myocardial infarction (MI), congestive center failing (CHF) and main CV occasions in those designated to the calcium mineral antagonists arm of treatment [Pahor tNSAIDs/COX-2 inhibitors Celecoxib tNSAIDs/COX-2 inhibitors Naproxen tNSAIDs/COX-2 inhibitor Eetoricoxib tNSAIDs/COX-2 inhibitors Diclofenac tNSAIDs/COX-2 inhibitors Principal endpoint Main vascular occasions: this is described a priori as any occurrence of pulmonary embolism, DVT, various other thromboembolic disorders and severe coronary syndromes (except MI that was analysed individually being a co-primary endpoint). Supplementary endpoints Stroke, cHF and hypertension Statistical evaluation The evaluation was conducted using Review Supervisor 5.1. For the dichotomous final result in this evaluation, the preferred way for each final result was the Peto chances ratio (OR) instead of using the fixed-effect MantelCHaenszel OR for dichotomous final results. The Peto OR is specially useful right here when the occasions under consideration aren’t very common as well as the research have similar quantities in the experimental and control hands. It gets the added benefit of not really needing a modification for zero cell count number [Green, 2008]. The 95% self-confidence interval, chi squared and diclofenac (Dining tables 2?2??Figures and C6 2?2??C6), celecoxib diclofenac (Dining tables 7?7?C10 and Numbers 7?7?C10), etoricoxib naproxen (Desk 11 and Shape 11), rofecoxib naproxen (Dining tables 12C13 and Numbers 12C13), rofecoxib diclofenac (Dining tables 14C15), rofecoxib naproxen (Dining tables 16C17), etoricoxib ibuprofen (Desk 18) and rofecoxib ibuprofen (Desk 19). Desk 2. Etoricoxib diclofenac for main vascular occasions. = 0.50); I2 = 0%. Check for overall impact: Z = 1.08 (= 0.28). CI, self-confidence interval; OR, chances ratio Desk 3. Etoricoxib diclofenac for myocardial infarction. = 0.10); I2 = 62%. Check for overall impact: Z = 0.26 (= 0.79). CI, self-confidence interval; OR, chances ratio. Desk 4. Etoricoxib diclofenac for heart stroke. = 0.85); I2 = 0%. Check for overall impact: Z = 1.35 (= 0.18). CI, self-confidence interval; OR, chances ratio. Desk 5. Etoricoxib diclofenac for hypertension. = 0.001); I2 = 85%. Check for overall impact: Z = 5.91 (= 0.00001). CI, self-confidence interval; OR, chances ratio. Desk 6. Etoricoxib diclofenac for congestive center failing. = 0.31); I2 = 15%. Check for overall impact: Z = 0.23 (= 0.82). CI, self-confidence interval; OR, chances ratio. Open up in another window Shape 2. Etoricoxib diclofenac for main vascular occasions. CI, confidence period. Open in another window Shape 3. Etoricoxib diclofenac for myocardial infarction. CI, self-confidence interval. Open up in another window Shape 4. Etoricoxib diclofenac for heart stroke. CI, confidence period. Open in another window Shape 5. Etoricoxib diclofenac for hypertension. CI, self-confidence interval. Open up in another window Shape 6. Etoricoxib diclofenac for congestive center failure. CI, self-confidence interval. Desk 7. Celecoxib diclofenac for main vascular occasions. = 0.02); I2 = 70%. Check for overall impact: Z = 0.13 (= 0.90). CI, self-confidence interval; OR, chances ratio. Desk 8. Celecoxib diclofenac for myocardial infarction. = 0.24); I2 = 30%. Check for overall impact: Z = 0.69 (= 0.49). CI, self-confidence interval; OR, chances ratio. Desk 9. Celecoxib diclofenac for heart stroke. = 0.54); I2 = 0%. Check for overall impact: Z = 2.19 (= 0.03). CI, self-confidence interval; OR, chances ratio. Desk 10. Celecoxib diclofenac for hypertension. = 0.99); I2 = 0%. Check for overall impact: Z = 0.67 (= 0.50). CI, self-confidence interval; OR, chances ratio. Open up in another window Shape 7. Celecoxib diclofenac for main vascular occasions. CI, confidence period. Open in another window Shape 8. Celecoxib diclofenac for myocardial infarction. CI, self-confidence interval. Open up.[2000]OAR12.512 weeks2591–1-R2512 weeks2571–0-Dic15012 weeks2682–3-Collantes et al. Using the principal endpoint of main vascular occasions (MVE) and a prespecified cutoff stage of just one 1.30, diclofenac (1 comparator) and rofecoxib (2 comparators) had increased risk for MVE [odds percentage (OR) >1.30]. Using the same requirements, diclofenac (1 comparator) got an increased threat of myocardial infarction (MI). Although celecoxib got a slightly improved risk for MI (OR 1.33, 1 comparator), the self-confidence period included 1 and had not been significant. For the supplementary endpoints, etoricoxib and rofecoxib had been considerably worse off for HT (1 comparator each) and naproxen was considerably worse off for heart stroke (1 comparator). Although ibuprofen was worse off for HT (1 comparator) the improved risk had not been significant. Summary: Through the analysis conducted, it would appear that the chance for cardiovascular occasions in arthritis individuals on licensed dosages of NSAIDs varies substantially and will probably depend on the average person compound. calcium mineral antagonist centered therapies as first-line medicines for hypertension recommended a considerably higher threat of severe myocardial infarction (MI), congestive center failing (CHF) and main CV occasions in those designated to the calcium mineral antagonists arm of treatment [Pahor tNSAIDs/COX-2 inhibitors Celecoxib tNSAIDs/COX-2 inhibitors Naproxen tNSAIDs/COX-2 inhibitor Eetoricoxib tNSAIDs/COX-2 inhibitors Diclofenac tNSAIDs/COX-2 inhibitors Major endpoint Main vascular occasions: this is described a priori as any event of pulmonary embolism, DVT, additional thromboembolic disorders and severe coronary syndromes (except MI that was analysed individually like a co-primary endpoint). Supplementary endpoints Stroke, cHF and hypertension Statistical evaluation The evaluation was carried out using Review Supervisor 5.1. For the dichotomous result in this evaluation, the preferred way for each result was the Peto chances ratio (OR) instead of using the fixed-effect MantelCHaenszel OR for dichotomous results. The Peto OR is specially useful right here when the occasions under consideration are certainly not very common as well as the research have similar numbers in the experimental and control arms. It has the added advantage of not needing a correction for zero cell count [Green, 2008]. The 95% confidence interval, chi squared and diclofenac (Tables 2?2??C6 and Figures 2?2??C6), celecoxib diclofenac (Tables 7?7?C10 and Figures 7?7?C10), etoricoxib naproxen (Table 11 and Figure 11), rofecoxib naproxen (Tables 12C13 and Figures 12C13), rofecoxib diclofenac (Tables 14C15), rofecoxib naproxen (Tables 16C17), etoricoxib ibuprofen (Table 18) and rofecoxib ibuprofen (Table 19). Table 2. Etoricoxib diclofenac for major vascular events. = 0.50); I2 = 0%. Test for overall effect: Z = 1.08 (= 0.28). CI, confidence interval; OR, odds ratio Table 3. Etoricoxib diclofenac for myocardial infarction. = 0.10); I2 = 62%. Test for overall effect: Z = 0.26 (= 0.79). CI, confidence interval; OR, odds ratio. Table 4. Etoricoxib diclofenac for stroke. = 0.85); I2 = 0%. Test for overall effect: Z = 1.35 (= 0.18). CI, confidence interval; OR, odds ratio. Table 5. Etoricoxib diclofenac for hypertension. = 0.001); I2 = 85%. Test for overall effect: Z = Retinyl acetate 5.91 (= 0.00001). CI, confidence interval; OR, odds ratio. Table 6. Etoricoxib diclofenac for congestive heart failure. = 0.31); I2 = 15%. Test for overall effect: Z = 0.23 (= 0.82). CI, confidence interval; OR, odds ratio. Open in a separate window Figure 2. Etoricoxib diclofenac for major vascular events. CI, confidence interval. Open in a separate window Figure 3. Etoricoxib diclofenac for myocardial infarction. CI, confidence interval. Open in a separate window Figure 4. Etoricoxib diclofenac for stroke. CI, confidence interval. Open in a separate window Figure 5. Etoricoxib diclofenac for hypertension. CI, confidence interval. Open in a separate window Figure 6. Etoricoxib diclofenac for congestive heart failure. CI, confidence interval. Table 7. Celecoxib diclofenac for major vascular events. = 0.02); I2 = 70%. Test for overall effect: Z = 0.13 (= 0.90). CI, confidence interval; OR, odds ratio. Table 8. Celecoxib diclofenac for myocardial infarction. = 0.24); I2 = 30%. Test for overall effect: Z = 0.69 (= 0.49). CI, confidence.Although ibuprofen was worse off for HT (1 comparator) the increased risk was not significant. Conclusion: From the analysis conducted, it appears that the risk for cardiovascular events in arthritis patients Retinyl acetate on licensed doses of NSAIDs varies considerably and is likely to depend on the individual compound. calcium antagonist based therapies as first-line drugs for hypertension suggested a significantly higher risk of acute myocardial infarction (MI), congestive heart failure (CHF) and major CV events in those assigned to the calcium antagonists arm of treatment [Pahor tNSAIDs/COX-2 inhibitors Celecoxib tNSAIDs/COX-2 inhibitors Naproxen tNSAIDs/COX-2 inhibitor Eetoricoxib tNSAIDs/COX-2 inhibitors Diclofenac tNSAIDs/COX-2 inhibitors Primary endpoint Major vascular events: this was defined a priori as any incident of pulmonary embolism, DVT, other thromboembolic disorders and acute coronary syndromes (except MI which was analysed separately as a co-primary endpoint). Secondary endpoints Stroke, hypertension and CHF Statistical analysis The analysis was conducted using Review Manager 5.1. and rofecoxib (2 comparators) had increased risk for MVE [odds ratio (OR) >1.30]. Using the same criteria, diclofenac (1 comparator) had an increased risk of myocardial infarction (MI). Although celecoxib had a slightly increased risk for MI (OR 1.33, 1 comparator), the confidence interval included 1 and was not significant. For the secondary endpoints, etoricoxib and rofecoxib were significantly worse off for HT (1 comparator each) and naproxen was significantly worse off for stroke (1 comparator). Although ibuprofen was worse off for HT (1 comparator) the increased risk was not significant. Conclusion: From the analysis conducted, it appears that the risk for cardiovascular events in arthritis patients on licensed doses of NSAIDs varies considerably and is likely to depend on the individual compound. calcium antagonist based therapies as first-line drugs for hypertension suggested a significantly higher risk of severe myocardial infarction (MI), congestive center failing (CHF) and main CV occasions in those designated to the calcium mineral antagonists arm of treatment [Pahor tNSAIDs/COX-2 inhibitors Celecoxib tNSAIDs/COX-2 inhibitors Naproxen tNSAIDs/COX-2 inhibitor Eetoricoxib tNSAIDs/COX-2 inhibitors Diclofenac tNSAIDs/COX-2 inhibitors Principal endpoint Main vascular occasions: this is described a priori as any occurrence of pulmonary embolism, DVT, various other thromboembolic disorders and severe coronary syndromes (except MI that was analysed individually being a co-primary endpoint). Supplementary endpoints Stroke, hypertension and CHF Statistical evaluation The evaluation was executed using Review Supervisor 5.1. For the dichotomous final result in this evaluation, the preferred way for each final result was the Peto chances ratio (OR) instead of using the fixed-effect MantelCHaenszel OR for dichotomous final results. The Peto OR is specially useful right here when the occasions under consideration aren’t very common as well as the research have similar quantities in the experimental and control hands. It gets the added benefit of not really needing a modification for zero cell count number [Green, 2008]. The 95% self-confidence interval, chi squared and diclofenac (Desks 2?2??C6 and Statistics 2?2??C6), celecoxib diclofenac (Desks 7?7?C10 and Numbers 7?7?C10), etoricoxib naproxen (Desk 11 and Amount 11), rofecoxib naproxen (Desks 12C13 and Numbers 12C13), rofecoxib diclofenac (Desks 14C15), rofecoxib naproxen (Desks 16C17), etoricoxib ibuprofen (Desk 18) and rofecoxib ibuprofen (Desk 19). Desk 2. Etoricoxib diclofenac for main vascular occasions. = 0.50); I2 = 0%. Check for overall impact: Z = 1.08 (= 0.28). CI, self-confidence interval; OR, chances ratio Desk 3. Etoricoxib diclofenac for myocardial infarction. = 0.10); I2 = 62%. Check for overall impact: Z = 0.26 (= 0.79). CI, self-confidence interval; OR, chances ratio. Desk 4. Etoricoxib diclofenac for heart stroke. = 0.85); I2 = 0%. Check for overall impact: Z = 1.35 (= 0.18). CI, self-confidence interval; OR, chances ratio. Desk 5. Etoricoxib diclofenac for hypertension. = 0.001); I2 = 85%. Check for overall impact: Z = 5.91 (= 0.00001). CI, self-confidence interval; OR, chances ratio. Desk 6. Etoricoxib diclofenac for congestive center failing. = 0.31); I2 = 15%. Check for overall impact: Z = 0.23 (= 0.82). CI, self-confidence interval; OR, chances ratio. Open up in another window Amount 2. Etoricoxib diclofenac for main vascular occasions. CI, confidence period. Open in another window Amount 3. Etoricoxib diclofenac for myocardial infarction. CI, self-confidence interval. Open up in another window Amount 4. Etoricoxib diclofenac for heart stroke. CI, confidence period. Open in another window Amount 5. Etoricoxib diclofenac for hypertension. CI, self-confidence interval. Open up in another window Amount 6. Etoricoxib diclofenac for congestive.[2002]RAE903 a few months353—012Nap10003 a few months181—05P3 a few months357—05Weisenhutter et al. myocardial infarction (MI). Although celecoxib acquired a slightly elevated risk for MI (OR 1.33, 1 comparator), the self-confidence period included 1 and had not been significant. For the supplementary endpoints, etoricoxib and rofecoxib had been considerably worse off for HT (1 comparator each) and naproxen was considerably worse off for heart stroke (1 comparator). Although ibuprofen was worse off for HT (1 comparator) the elevated risk had not been significant. Bottom line: In the analysis conducted, it would appear that the chance for cardiovascular occasions in arthritis sufferers on licensed dosages of NSAIDs varies significantly and will probably depend on the average person compound. calcium mineral antagonist structured therapies as first-line medications for hypertension recommended a considerably higher threat of severe myocardial infarction (MI), congestive center failing (CHF) and main CV occasions in those designated to the calcium mineral antagonists arm of treatment [Pahor tNSAIDs/COX-2 inhibitors Celecoxib tNSAIDs/COX-2 inhibitors Naproxen tNSAIDs/COX-2 inhibitor Eetoricoxib tNSAIDs/COX-2 inhibitors Diclofenac tNSAIDs/COX-2 inhibitors Principal endpoint Main vascular occasions: this is described a priori as any occurrence of pulmonary embolism, DVT, various other thromboembolic disorders and severe coronary syndromes (except MI that was analysed separately as a co-primary endpoint). Secondary endpoints Stroke, hypertension and CHF Statistical analysis The analysis was conducted using Review Manager 5.1. For the dichotomous outcome in this analysis, the preferred method for each outcome was the Peto odds ratio (OR) as opposed to using the fixed-effect MantelCHaenszel OR for dichotomous outcomes. The Peto OR is particularly useful here when the events under consideration are not very common and the studies have similar numbers in the experimental and control arms. It has the added advantage of not needing a correction for zero cell count [Green, 2008]. The 95% confidence interval, chi squared and diclofenac (Tables 2?2??C6 and Figures 2?2??C6), celecoxib diclofenac (Tables 7?7?C10 and Figures 7?7?C10), etoricoxib naproxen Rabbit Polyclonal to OR2T2 (Table 11 and Determine 11), rofecoxib naproxen (Tables 12C13 and Figures 12C13), rofecoxib diclofenac (Tables 14C15), rofecoxib naproxen (Tables 16C17), etoricoxib ibuprofen (Table 18) and rofecoxib ibuprofen (Table 19). Table 2. Etoricoxib diclofenac for major vascular events. = 0.50); I2 = 0%. Test for overall effect: Z = 1.08 (= 0.28). CI, confidence interval; OR, odds ratio Table 3. Etoricoxib diclofenac for myocardial infarction. = 0.10); I2 = 62%. Test for overall effect: Z = 0.26 (= 0.79). CI, confidence interval; OR, odds ratio. Table 4. Etoricoxib diclofenac for stroke. = 0.85); I2 = 0%. Test for overall effect: Z = 1.35 (= 0.18). CI, confidence interval; OR, odds ratio. Table 5. Etoricoxib diclofenac for hypertension. = 0.001); I2 = 85%. Test for overall effect: Z = 5.91 (= 0.00001). CI, confidence interval; OR, odds ratio. Table 6. Etoricoxib diclofenac for congestive heart failure. = 0.31); I2 = 15%. Test for overall effect: Z = 0.23 (= 0.82). CI, confidence interval; OR, odds ratio. Open in a separate window Physique 2. Etoricoxib diclofenac for major vascular events. CI, confidence interval. Open in a separate window Physique 3. Etoricoxib diclofenac for myocardial infarction. CI, confidence interval. Open in a separate window Physique 4. Etoricoxib diclofenac for stroke. CI, confidence interval. Open in a separate window Physique 5. Etoricoxib diclofenac for hypertension. CI, confidence interval. Open in a separate window Physique 6. Etoricoxib diclofenac for congestive heart failure. CI, confidence interval. Table 7. Celecoxib diclofenac for major vascular events. = 0.02); I2 = 70%. Test for overall effect: Z = 0.13 (= 0.90). CI, confidence interval; OR, odds ratio. Table 8. Celecoxib diclofenac for myocardial infarction. = 0.24); I2 = 30%. Test for overall effect: Z = 0.69 (= 0.49). CI, confidence interval; OR, odds ratio. Table 9. Celecoxib diclofenac for stroke. = 0.54); I2 = 0%. Test for overall effect: Z = 2.19 (= 0.03). CI, confidence interval; OR, odds ratio. Table 10. Celecoxib diclofenac for hypertension. = 0.99); I2 = 0%. Test for overall effect: Z = 0.67 (= 0.50). CI, confidence interval; OR, odds ratio. Open in a separate window Physique 7. Celecoxib diclofenac for major vascular events. CI, confidence interval. Open in a separate window Physique 8. Celecoxib diclofenac for myocardial infarction. CI, self-confidence interval. Open up in another window Shape 9. Celecoxib diclofenac for heart stroke. CI, confidence period. Open in another window Shape 10. Celecoxib diclofenac for hypertension..This may not provide clinicians with important information they want when working with these drugs for licensed indications, where in fact the great things about treatment (treatment) is clear and quantifiable weighed against when the drug can be used for preventive purposes. In conclusion, the consequence of this analysis shows that the danger of experiencing a CV event varies considerably when arthritis individuals use NSAIDs at licensed doses for symptom control, and moreover, this risk is apparently compound dependent. somewhat improved risk for MI (OR 1.33, 1 comparator), the self-confidence period included 1 and had not been significant. For the supplementary endpoints, etoricoxib and rofecoxib had been considerably worse off for HT (1 comparator each) and naproxen was considerably worse off for heart stroke (1 comparator). Although ibuprofen was worse off for HT (1 comparator) the improved risk had not been significant. Summary: Through the analysis conducted, it would appear that the chance for cardiovascular occasions in arthritis individuals on licensed dosages of NSAIDs varies substantially and will probably depend on the average person compound. calcium mineral antagonist centered therapies as first-line medicines for hypertension recommended a considerably higher threat of severe myocardial infarction (MI), congestive center failing (CHF) and main CV occasions in those designated to the calcium mineral antagonists arm of treatment [Pahor tNSAIDs/COX-2 inhibitors Celecoxib tNSAIDs/COX-2 inhibitors Naproxen tNSAIDs/COX-2 inhibitor Eetoricoxib tNSAIDs/COX-2 inhibitors Diclofenac tNSAIDs/COX-2 inhibitors Major endpoint Main vascular occasions: this is described a priori as any event of pulmonary embolism, DVT, additional thromboembolic disorders and severe coronary syndromes (except MI that was analysed individually like a co-primary endpoint). Supplementary endpoints Stroke, hypertension and CHF Statistical evaluation The evaluation was carried out using Review Supervisor 5.1. For the dichotomous result in this evaluation, the preferred way for each result was the Peto chances ratio (OR) instead of using the fixed-effect MantelCHaenszel OR for dichotomous results. The Peto OR is specially useful right here when the occasions under consideration are certainly not very common as well as the research have similar amounts in the experimental and control hands. It gets the added benefit of not really needing a modification for zero cell count number [Green, 2008]. The 95% self-confidence interval, chi squared and diclofenac (Dining tables 2?2??C6 and Numbers 2?2??C6), celecoxib diclofenac (Dining tables 7?7?C10 and Numbers 7?7?C10), etoricoxib naproxen (Desk 11 and Shape 11), rofecoxib naproxen (Dining tables 12C13 and Numbers 12C13), rofecoxib diclofenac (Dining tables 14C15), rofecoxib naproxen (Dining tables 16C17), etoricoxib ibuprofen (Desk 18) and rofecoxib ibuprofen (Desk 19). Desk 2. Etoricoxib diclofenac for main vascular occasions. = 0.50); I2 = 0%. Check for overall impact: Z = 1.08 (= 0.28). CI, self-confidence interval; OR, chances ratio Desk 3. Etoricoxib diclofenac for myocardial infarction. = 0.10); I2 = 62%. Check for overall impact: Z = 0.26 (= 0.79). CI, self-confidence interval; OR, chances ratio. Desk 4. Etoricoxib diclofenac for heart stroke. = 0.85); I2 = 0%. Check for overall impact: Z = 1.35 (= 0.18). CI, self-confidence interval; OR, chances ratio. Desk 5. Etoricoxib diclofenac for hypertension. = 0.001); I2 = 85%. Check for overall impact: Z = 5.91 (= 0.00001). CI, self-confidence interval; OR, chances ratio. Desk 6. Etoricoxib diclofenac for congestive center failing. = 0.31); I2 = 15%. Check for overall impact: Z = 0.23 (= 0.82). CI, self-confidence interval; OR, chances ratio. Open up in another window Shape 2. Etoricoxib diclofenac for main vascular occasions. CI, confidence period. Open in another window Shape 3. Etoricoxib diclofenac for myocardial infarction. CI, self-confidence interval. Open up in another window Shape 4. Etoricoxib diclofenac for heart stroke. CI, confidence period. Open in another window Shape 5. Etoricoxib diclofenac for hypertension. CI, self-confidence interval. Open up in another window Number 6. Etoricoxib diclofenac for congestive heart failure. CI, confidence interval. Table 7. Celecoxib diclofenac for major vascular events. = 0.02); I2 = 70%. Test for overall effect: Z = 0.13 (= 0.90). CI, confidence interval; OR, odds ratio. Table 8. Celecoxib diclofenac Retinyl acetate for myocardial infarction. = 0.24); I2 = 30%. Test for overall effect: Z = 0.69 (= 0.49). CI, confidence interval; Retinyl acetate OR, odds ratio. Table 9. Celecoxib diclofenac for stroke. = 0.54); I2 = 0%. Test for overall effect: Z = 2.19 (= 0.03). CI, confidence interval; OR, odds ratio. Table 10. Celecoxib diclofenac for hypertension. = 0.99); I2 = 0%. Test for overall effect: Z = 0.67 (= 0.50). CI, confidence interval; OR, odds ratio. Open in a separate window Number 7. Celecoxib diclofenac for major vascular events. CI, confidence interval. Open in a separate window Number 8. Celecoxib diclofenac for myocardial infarction. CI, confidence interval. Open in a separate window Number 9. Celecoxib diclofenac for stroke. CI, confidence interval. Open in a separate window Number 10. Celecoxib diclofenac for hypertension. CI, confidence interval. Table 11. Etoricoxib naproxen for hypertension. = 1.00); I2 = 0%. Test for overall effect: Z = 0.50 (= 0.62). CI, confidence interval; OR, odds.
